- ICH GCP
- Yhdysvaltain kliinisten tutkimusten rekisteri
- Kliininen tutkimus NCT07598656
Local Delivery of Lactobacillus Reuteri Probiotic as An Adjunct to Non-surgical Periodontal Therapy in Patients With Stage II, III, and IV Periodontitis and Type 2 Diabetes Mellitus
Local Delivery of Lactobacillus Reuteri Probiotic as An Adjunct to Non-surgical Periodontal Therapy in Patients With Stage II, III, and IV Periodontitis and Type 2 Diabetes Mellitus: A Prospective Split-Mouth Clinical Trial
The purpose of the study is to evaluate the effectiveness of local delivery of Lactobacillus reuteri probiotic on periodontitis patients with type 2 diabetes mellitus, as an adjunct to non-surgical periodontal treatment. To date, the efficacy of local drug delivery as an adjunct has been established, whereas research on the effectiveness of probiotics as an adjunct remains limited. Specifically, there is a lack of studies focusing on the clinical effectiveness of Lactobacillus reuteri probiotic as an adjunct in subgingival debridement for patients with type 2 diabetes mellitus.
Over the past decade, there has been a growing interest in using probiotics to enhance periodontal health. Subsequent studies investigated the application of probiotics in individuals with periodontal disease, concluding that the depth of periodontal pockets in humans also decreases with probiotic use as part of periodontal treatment. Positive effects of probiotics have been reported at both the microbiological and immunological levels. Lactobacillus reuteri probiotic has also shown a notable decrease in pro-inflammatory markers and an increase in anti-inflammatory markers. Despite these findings, the clinical application of Lactobacillus reuteri probiotics in patients with type 2 diabetes mellitus has not yet been explored. Your participation will be about 6months duration.
If you agree to participate in the study, the doctor (YKZ) may need to perform some tests and examinations to determine if you are suitable for the study. If you are deemed suitable, you will be assigned to both of the treatment groups below (split-mouth study design). Both right (quadrant 1 and 4) and left (quadrant 2 and 3) halves will be assigned randomly to one of the two treatment modalities. The study products do not contain porcine, bovine or animal components.
- Oral hygiene instructions (OHI) + Professional mechanical plaque removal
- Root surface debridement (RSD)
- (a) Test group: L. reuteri probiotic subgingival applications on all pockets of ≥ 5mm
3. (b) Control group: Sterilised distilled water subgingival applications on all pockets of ≥ 5mm 4. The applications will be repeated again in both groups after initial applications on every 7, 14, 21 and 28 day.
Participating in this study, you will receive a complete set of oral hygiene kit. While participating, you may or may not experience direct benefits.
The risks for probiotic adjunctive non-surgical periodontal therapy, while generally considered safe, may pose some potential risk factors. Some potential risk factors may include:
- Temporary discomfort; Some individuals may experience temporary discomfort or pain following non-surgical periodontal procedures, such as scaling and root surface debridement. This discomfort typically subsides within a few days.
- Gingival and/ or root sensitivity; Some individuals may experience increased sensitivity in the gums or teeth, particularly to hot or cold temperatures, after non-surgical periodontal therapy.
- Bleeding gums; Individuals might notice temporary bleeding from the gums, especially during and immediately after the procedure. This is usually minor and resolves with proper post-operative care.
- Recession of gums; In rare instances, there may be a risk of gingival recession, where the gums pull away from the teeth. This is more likely in individuals with thin or fragile gum tissue.
- Infection; While rare, there is a potential risk of infection, particularly if proper hygiene practices are not followed after the procedure.
- Allergic reactions; Some individuals may be allergic to probiotic used during adjunctive non-surgical periodontal therapy, leading to allergic reactions (skin rashes or itchiness).
If you require additional information regarding risks and side effects, please consult your study doctor (YKZ). The trial staff will promptly update you on any new discoveries or modifications to the study product that may impact your health or willingness to continue in this study. If needed, you may be requested to provide your consent to participate again.
Nonetheless, the data and information collected will contribute to advancing the treatment or management of individuals with the same disease or condition.
Yes, you have the right to refuse to take part in the study at any time. You do not have to participate in this study to get treatment for your periodontal disease. Your participation in the research is entirely voluntary, and you can choose not to participate without any obligation or negative consequences.
Tutkimuksen yleiskatsaus
Tila
Ehdot
Interventio / Hoito
Opintotyyppi
Ilmoittautuminen (Todellinen)
Vaihe
- Ei sovellettavissa
Yhteystiedot ja paikat
Opiskelupaikat
-
-
Selangor
-
Hulu Langat, Selangor, Malesia, 42610
- Mahsa University
-
-
Osallistumiskriteerit
Kelpoisuusvaatimukset
Opintokelpoiset iät
- Aikuinen
- Vanhempi Aikuinen
Hyväksyy terveitä vapaaehtoisia
Kuvaus
Inclusion Criteria:
- Individuals aged between 18 and 65 years;
- Diagnosed with controlled type 2 diabetes mellitus (HbA1c < 7%);
- Presence of a minimum of 20 natural teeth;
- Untreated stage II, III, or IV periodontitis (Tonetti et al., 2018), with radiographic evidence of generalized alveolar bone loss;
- At least one periodontal pocket per quadrant with a probing pocket depth of 5 mm and bleeding on probing.
Exclusion Criteria:
- Participation in another clinical trial;
- Pregnancy or lactation;
- Smoker;
- Individuals with autoimmune diseases;
- Individuals with compromized medical conditions requiring prophylactic antibiotic therapy (e.g., patients with valvular prosthesis, patients with history of infective endocarditis, heart transplant recipients, etc.);
- Individuals currently receiving ongoing drug therapy (corticosteroid, bisphosphonates, nonsteroidal anti-inflammatory drugs, etc.);
- Use of systemic antibiotics within the 3 months prior to the study;
- Use of probiotic products within the 3 months prior to the study;
- History of subgingival instrumentation within the previous 6 months;
- Presence of acute periodontal lesions and/or endo-periodontal lesions (Herrera et al., 2018);
- Physical limitations that may interfere proper oral hygiene practices.
Opintosuunnitelma
Miten tutkimus on suunniteltu?
Suunnittelun yksityiskohdat
- Ensisijainen käyttötarkoitus: Hoito
- Jako: Satunnaistettu
- Inventiomalli: Rinnakkaistehtävä
- Naamiointi: Yksittäinen
Aseet ja interventiot
Osallistujaryhmä / Arm |
Interventio / Hoito |
|---|---|
|
Kokeellinen: Probiotic Test group
Lactobacillus reuteri probiotic drops (a minimum of 100 colony forming units Lactobacillus reuteri DSM 17938 Protectis drops, BioGaia AB, Turnhout, Belgium) were administered subgingivally at the test sites
|
Applied with a syringe and blunt needle until overflowing from the periodontal pocket.
|
|
Active Comparator: Distilled Water Control group
Sterile distilled water was administered subgingivally at the control sites
|
Applied with a syringe and blunt needle until overflowing from the periodontal pocket.
|
Mitä tutkimuksessa mitataan?
Ensisijaiset tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
|---|---|---|
|
Change from baseline in the periodontal probing depth at 3 months and 6 months
Aikaikkuna: From enrollment to the end of treatment at 6 months
|
Probing pocket depth was measured as the distance from the free gingival margin (FGM) to the base of the periodontal pocket.
All measurements were recorded to the nearest millimeter using a standardized and graduated UNC-15 periodontal probe.
Six sites per tooth were examined, namely mesio-buccal, mid-buccal, disto-buccal, mesio-lingual, mid-lingual, and disto-lingual.
|
From enrollment to the end of treatment at 6 months
|
Toissijaiset tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
|---|---|---|
|
Change from baseline in the plaque index at 3 months and 6 months
Aikaikkuna: From enrollment to the end of treatment at 6 months
|
Score 0 = No plaque in the gingival area. Score 1 = A film of plaque adhering to the free gingival margin and adjacent area of the tooth. The plaque may only be recognized by running a probe across the tooth surface. Score 2 = Moderate accumulation of soft deposits within the gingival pocket, on the gingival margin and/or adjacent tooth surface, which can be seen by the naked eye. Score 3 = Abundance of soft matter within the gingival pocket and/ or on the gingival margin and adjacent tooth surface. |
From enrollment to the end of treatment at 6 months
|
|
Change from baseline in the gingival index at 3 months and 6 months
Aikaikkuna: From enrollment to the end of treatment at 6 months
|
Score 0 = Normal gingiva. Score 1 = Mild inflammation - slight change in color, slight oedema. No bleeding on probing. Score 2 = Moderate inflammation - redness, oedema and glazing. Bleeding on probing. Score 3 = Severe inflammation - marked redness and oedema. Ulceration. Tendency to spontaneous bleeding. |
From enrollment to the end of treatment at 6 months
|
|
Change from baseline in the bleeding on probing at 3 months and 6 months
Aikaikkuna: From enrollment to the end of treatment at 6 months
|
Score 0 = Healthy looking papillary and marginal gingiva. No bleeding on probing. Score 1 = Healthy looking gingiva. Bleeding on probing. Score 2 = Bleeding on probing. Change in color, no oedema. Score 3 = Bleeding on probing. Change in color, slight oedema. Score 4 = Bleeding on probing. Change in color, obvious oedema. Score 5 = Spontaneous bleeding. Change in color, marked oedema. |
From enrollment to the end of treatment at 6 months
|
|
Change from baseline in the clinical attachment level at 3 months and 6 months
Aikaikkuna: From enrollment to the end of treatment at 6 months
|
Clinical attachment level was measured as the distance from the cemento-enamel junction (CEJ) of the tooth to the base of the periodontal pocket.
All measurements were recorded to the nearest millimeter using a standardized and graduated UNC-15 periodontal probe.
Six sites per tooth were examined, namely mesio-buccal, mid-buccal, disto-buccal, mesio-lingual, mid-lingual, and disto-lingual.
|
From enrollment to the end of treatment at 6 months
|
Yhteistyökumppanit ja tutkijat
Sponsori
Opintojen ennätyspäivät
Opi tärkeimmät päivämäärät
Opiskelun aloitus (Todellinen)
Ensisijainen valmistuminen (Todellinen)
Opintojen valmistuminen (Todellinen)
Opintoihin ilmoittautumispäivät
Ensimmäinen lähetetty
Ensimmäinen toimitettu, joka täytti QC-kriteerit
Ensimmäinen Lähetetty (Todellinen)
Tutkimustietojen päivitykset
Viimeisin päivitys julkaistu (Todellinen)
Viimeisin lähetetty päivitys, joka täytti QC-kriteerit
Viimeksi vahvistettu
Lisää tietoa
Tähän tutkimukseen liittyvät termit
Muita asiaankuuluvia MeSH-ehtoja
Muut tutkimustunnusnumerot
- RMC/MAR/2024/EC18
Lääke- ja laitetiedot, tutkimusasiakirjat
Tutkii yhdysvaltalaista FDA sääntelemää lääkevalmistetta
Tutkii yhdysvaltalaista FDA sääntelemää laitetuotetta
Yhdysvalloissa valmistettu ja sieltä viety tuote
Nämä tiedot haettiin suoraan verkkosivustolta clinicaltrials.gov ilman muutoksia. Jos sinulla on pyyntöjä muuttaa, poistaa tai päivittää tutkimustietojasi, ota yhteyttä register@clinicaltrials.gov. Heti kun muutos on otettu käyttöön osoitteessa clinicaltrials.gov, se päivitetään automaattisesti myös verkkosivustollemme .
Kliiniset tutkimukset Diabetes
-
University of Colorado, DenverMassachusetts General Hospital; Beta Bionics, Inc.ValmisDiabetes mellitus, tyyppi 1 | Tyypin 1 diabetes | Diabetes tyyppi 1 | Tyypin 1 diabetes mellitus | Autoimmuuni Diabetes | Diabetes mellitus, insuliinista riippuvainen | Nuorten diabetes | Diabetes, Autoimmuuni | Insuliiniriippuvainen diabetes mellitus 1 | Diabetes mellitus, insuliinista riippuvainen, 1 | Diabetes... ja muut ehdotYhdysvallat
-
University of Colorado, DenverMassachusetts General Hospital; Ann & Robert H Lurie Children's Hospital... ja muut yhteistyökumppanitRekrytointiDiabetes mellitus | Diabetes | Tyypin 2 diabetes | Tyypin 2 diabetes mellitus | Diabetes mellitus, tyyppi I | Diabetes mellitus tyyppi II | Diabetes mellitus, insuliinista riippuvainen | Diabetes, Autoimmuuni | Tyypin 1 diabetes (T1D) | Tyypin 2 diabetes insuliinilla | Diabetes, tyyppi IIYhdysvallat
-
Universite du Quebec en OutaouaisUniversity Hospital, Angers; McGill University; Centre de Recherche du Centre...Ei vielä rekrytointiaDiabetes mellitus, tyyppi 1 | Diabetes, Autoimmuuni | Diabetes tyyppi 2 | Diabetes; Alku aikuisenaKanada
-
Guang NingRekrytointiTyypin 2 diabetes mellitus | Tyypin 1 diabetes mellitus | Monogeneettinen diabetes | Pankreatogeeninen diabetes | Huumeiden aiheuttama diabetes mellitus | Muut diabetes mellituksen muodotKiina
-
Tianjin Medical University General HospitalRekrytointiVastasyntyneiden diabetes | Monogeeninen diabetes | Nuorten aikuisten diabetesKiina
-
VeraLight, Inc.InLight SolutionsTuntematonRaskausajan diabetes | Insuliiniriippuvainen diabetes | Insuliinista riippumaton diabetesYhdysvallat
-
KOS Inc.Ei vielä rekrytointiaDiabetes mellitus, tyyppi 2 | Diabetes | Prediabetes | Diabetes mellitus, tyypin 1 diabetesYhdysvallat
-
University of North Carolina, Chapel HillAmerican Heart AssociationRekrytointiTyypin 2 diabetes | Ravitsemus | Tyypin 2 diabetes | T2DM (tyypin 2 diabetes) | Diabetes melliitti | T2DM | Diabetes koulutusYhdysvallat
-
University of North Carolina, Chapel HillAmerican Diabetes AssociationEi vielä rekrytointiaTyypin 2 diabetes (T2DM) | Diabetes (DM) | Insuliiniriippuvainen diabetes | Tyypin 1 diabetes (T1D) | Diabetes koulutus | Diabeteksen hoito | Diabetes (insuliinia koskeva, tyyppi 1 tai tyyppi 2)Yhdysvallat
-
Endogenex, Inc.Ei vielä rekrytointiaDiabetes mellitus, tyyppi 2 | Diabetes | Tyypin 2 diabetes mellitus | Tyypin 2 diabetes | Tyypin 2 diabetes
Kliiniset tutkimukset Lactobacillus reuteri DSM 17938
-
University of Colorado, BoulderValmisMasennusoireet | Ahdistuneisuuden oireet | Koettu stressiYhdysvallat
-
Medical University of WarsawValmisGastroenteriitti | Ripuli | Nosokomiaalinen infektioPuola
-
Örebro University, SwedenBioGaia ABValmisVatsakipu | Ummetus | Ripuli | Refluksi | RuoansulatushäiriötRuotsi
-
Vastra Gotaland RegionValmisInsuliiniresistenssi | Tyypin 2 diabetesRuotsi
-
Medical University of WarsawValmis
-
Szpital im. Św. Jadwigi ŚląskiejValmisAkuutti gastroenteriittiPuola
-
Hospital General Naval de Alta Especialidad - Escuela...Tuntematon
-
Children's Hospital and Institute of Child Health...TuntematonSepsis | Nekrotisoiva enterokoliitti
-
Children's Memorial Health Institute, PolandTuntematon
-
Medical University of WarsawValmis